Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.10
NAS:NKTR's Cash to Debt is ranked lower than
80% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:NKTR: 1.10 )
Ranked among companies with meaningful Cash to Debt only.
NAS:NKTR' s Cash to Debt Range Over the Past 10 Years
Min: 0.72  Med: 1.44 Max: 389.59
Current: 1.1
0.72
389.59
Equity to Asset -0.09
NAS:NKTR's Equity to Asset is ranked lower than
92% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:NKTR: -0.09 )
Ranked among companies with meaningful Equity to Asset only.
NAS:NKTR' s Equity to Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.33 Max: 0.91
Current: -0.09
-0.21
0.91
F-Score: 2
Z-Score: -2.39
M-Score: 6.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -40.19
NAS:NKTR's Operating margin (%) is ranked higher than
59% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:NKTR: -40.19 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:NKTR' s Operating margin (%) Range Over the Past 10 Years
Min: -173.91  Med: -76.91 Max: -8.21
Current: -40.19
-173.91
-8.21
Net-margin (%) -68.30
NAS:NKTR's Net-margin (%) is ranked higher than
53% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:NKTR: -68.30 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:NKTR' s Net-margin (%) Range Over the Past 10 Years
Min: -211.67  Med: -54.58 Max: -12
Current: -68.3
-211.67
-12
ROE (%) -1588.61
NAS:NKTR's ROE (%) is ranked lower than
99% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:NKTR: -1588.61 )
Ranked among companies with meaningful ROE (%) only.
NAS:NKTR' s ROE (%) Range Over the Past 10 Years
Min: -1588.61  Med: -62.99 Max: -14.84
Current: -1588.61
-1588.61
-14.84
ROA (%) -27.60
NAS:NKTR's ROA (%) is ranked higher than
50% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:NKTR: -27.60 )
Ranked among companies with meaningful ROA (%) only.
NAS:NKTR' s ROA (%) Range Over the Past 10 Years
Min: -34.75  Med: -17.63 Max: -4.39
Current: -27.6
-34.75
-4.39
ROC (Joel Greenblatt) (%) -124.81
NAS:NKTR's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:NKTR: -124.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:NKTR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -182.91  Med: -75.33 Max: -9.76
Current: -124.81
-182.91
-9.76
Revenue Growth (3Y)(%) 35.10
NAS:NKTR's Revenue Growth (3Y)(%) is ranked higher than
84% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:NKTR: 35.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:NKTR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.6  Med: 8.4 Max: 58.7
Current: 35.1
-31.6
58.7
EBITDA Growth (3Y)(%) -41.20
NAS:NKTR's EBITDA Growth (3Y)(%) is ranked lower than
89% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:NKTR: -41.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:NKTR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.5  Med: 9.6 Max: 109.1
Current: -41.2
-71.5
109.1
EPS Growth (3Y)(%) -25.90
NAS:NKTR's EPS Growth (3Y)(%) is ranked lower than
76% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:NKTR: -25.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:NKTR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.4  Med: 3.6 Max: 100.5
Current: -25.9
-44.4
100.5
» NAS:NKTR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

NKTR Guru Trades in Q3 2015

Steven Cohen 137,500 sh (New)
PRIMECAP Management 19,743,886 sh (+0.19%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
» More
Q4 2015

NKTR Guru Trades in Q4 2015

PRIMECAP Management 19,784,286 sh (+0.20%)
Steven Cohen 17,500 sh (-87.27%)
» More
Q1 2016

NKTR Guru Trades in Q1 2016

Paul Tudor Jones 13,700 sh (New)
PRIMECAP Management 20,010,086 sh (+1.14%)
Steven Cohen 9,200 sh (-47.43%)
» More
Q2 2016

NKTR Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
PRIMECAP Management 20,002,586 sh (-0.04%)
» More
» Details

Insider Trades

Latest Guru Trades with NKTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ARIA, OTCPK:LBTSF, NAS:BLUE, NAS:KITE, NAS:LGND, NAS:SRPT, OTCPK:SOLTF, NAS:RARE, OTCPK:ABCZY, NYSE:PBYI, NAS:PRTA, NAS:OPHT, NAS:AGIO, NAS:JUNO, NAS:LXRX, NYSE:XON, OTCPK:BTGGF, NAS:GLPG, NAS:ONCE, NAS:ITCI » details
Traded in other countries:ITH.Germany,
Nektar Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops a pipeline of drug candidates that utilizes its PEGylation and polymer conjugate technology platforms that are designed to develop molecular entities.

Nektar Therapeutics Inc was incorporated in July 1990 and reincorporated in Delaware in 1998. The Company is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. The Company creates its drug candidates by using its proprietary polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new molecular entities. The Company's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain. OIC is a common side effect of prescription opioids when used for chronic pain management. In September 2009, the Company entered into a global license agreement with AstraZeneca AB for the development and commercialization of NKTR-118 and NKTR-119. NKTR-119 is an early stage research and development program that is designed to combine various opioids with NKTR-118. AstraZeneca is responsible for all clinical, regulatory and commercialization costs for NKTR-118 and NKTR-119. The Company has several proprietary pre-clinical and clinical drug candidates that are in the pain therapeutic area. NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies. The Company also has a collaboration with Bayer Healthcare LLC "Bayer" to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic. Bayer has initiated a Phase 3 clinical development of BAY41-6551 with the first patient enrolled in April 2013. The Company frequently competes with pharmaceutical companies and other institutions. As a manufacturer of PEG reagents for the U.S. market, the Company is subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change freque.

Ratios

vs
industry
vs
history
P/S 12.46
NKTR's P/S is ranked lower than
52% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. NKTR: 12.46 )
Ranked among companies with meaningful P/S only.
NKTR' s P/S Range Over the Past 10 Years
Min: 1.76  Med: 8.82 Max: 16.57
Current: 12.46
1.76
16.57
Current Ratio 4.02
NKTR's Current Ratio is ranked lower than
53% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. NKTR: 4.02 )
Ranked among companies with meaningful Current Ratio only.
NKTR' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 5.86 Max: 16.32
Current: 4.02
1
16.32
Quick Ratio 3.89
NKTR's Quick Ratio is ranked lower than
52% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. NKTR: 3.89 )
Ranked among companies with meaningful Quick Ratio only.
NKTR' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5.83 Max: 16.32
Current: 3.89
0.96
16.32
Days Inventory 122.81
NKTR's Days Inventory is ranked higher than
52% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. NKTR: 122.81 )
Ranked among companies with meaningful Days Inventory only.
NKTR' s Days Inventory Range Over the Past 10 Years
Min: 33.21  Med: 121.03 Max: 185.48
Current: 122.81
33.21
185.48
Days Sales Outstanding 53.09
NKTR's Days Sales Outstanding is ranked higher than
57% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. NKTR: 53.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
NKTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.46  Med: 27.52 Max: 79.04
Current: 53.09
5.46
79.04
Days Payable 26.80
NKTR's Days Payable is ranked lower than
72% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. NKTR: 26.80 )
Ranked among companies with meaningful Days Payable only.
NKTR' s Days Payable Range Over the Past 10 Years
Min: 8.88  Med: 35.37 Max: 144.1
Current: 26.8
8.88
144.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.50
NKTR's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. NKTR: -5.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NKTR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: -7.3 Max: -0.7
Current: -5.5
-17.6
-0.7

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.41
NKTR's Price/Median PS Value is ranked lower than
73% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. NKTR: 1.41 )
Ranked among companies with meaningful Price/Median PS Value only.
NKTR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 1.15 Max: 4.83
Current: 1.41
0.22
4.83
Earnings Yield (Greenblatt) (%) -3.75
NKTR's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. NKTR: -3.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NKTR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3.81  Med: 3.6 Max: 4.9
Current: -3.75
-3.81
4.9

More Statistics

Revenue (TTM) (Mil) $191.0
EPS (TTM) $ -0.96
Beta1.62
Short Percentage of Float13.41%
52-Week Range $9.92 - 19.98
Shares Outstanding (Mil)136.73

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 172 202 260 370
EPS ($) -1.22 -0.70 -0.31 0.30
EPS w/o NRI ($) -1.22 -0.70 -0.31 0.30
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:NKTR

Headlines

Articles On GuruFocus.com
Weekly CEO Sales Highlight: Monolithic Power Systems, Five Prime Therapeutics, Nektar Therapeutics Feb 15 2016 
Weekly CEO Sells Highlight: Cadence Design Systems Inc., Nektar Therapeutics Inc., Netflix Inc., Pho Sep 27 2015 
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 

More From Other Websites
Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo Sep 28 2016
Nektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : September 28,... Sep 28 2016
Big Pharma partners with another Bay Area company in cancer immunotherapy quest Sep 27 2016
NEKTAR THERAPEUTICS Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Sep 27 2016
Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration... Sep 27 2016
Bristol-Myers to test Opdivo with Nektar drug for several cancers Sep 27 2016
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate... Sep 27 2016
Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy Sep 27 2016
7:00 am Nektar Therapeutics announces a collaboration to evaluate Bristol-Myers Squibb's (Sep 27 2016
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate... Sep 27 2016
The opioids of the future won't get you high Sep 18 2016
4 stocks to watch Sep 14 2016
Two Californian research teams are on the path to ending the opioid crisis — and their drugs have... Sep 13 2016
Nektar And Three Other Momentum Stocks With Bullish Charts Sep 08 2016
[$$] Two Biotech CEOs Make $1M Stock Sales Sep 08 2016
4 stocks to watch Sep 07 2016
Mobileye And Three More Stocks Breaking Out Aug 24 2016
ETF’s with exposure to Nektar Therapeutics : August 22, 2016 Aug 22 2016
NEKTAR THERAPEUTICS Financials Aug 12 2016
ETF’s with exposure to Nektar Therapeutics : August 11, 2016 Aug 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)